Dear Valued Customer,

Did you know that QIAGEN’s global partnership with Helix can help you keep and accelerate your clinical trial timelines in hereditary diseases?

The speed and success of trial recruitment greatly impacts the timelines of your clinical trial. What if you could quickly recruit the right individuals for your trials?

The world-leading population genomics database created by Helix – using its FDA-cleared Exome+® assay – enables you to accurately identify individuals who meet your trial criteria in hereditary diseases. By reducing screening failure rates, you can shorten trial length.

Discover how you can increase the speed of clinical trial enrollment in hereditary diseases.